Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shares in drugmaker Sobi tumble as Advent, Aurora withdraw $8 billion bid

12/03/2021 | 08:49am EST
FILE PHOTO: The logo for Singapore sovereign wealth fund GIC Pte Ltd, is seen on a building in Singapore

STOCKHOLM (Reuters) -Shares in Sweden's Orphan Biovitrum (Sobi) plunged 23% on Friday after U.S. private equity firm Advent International and Singapore's sovereign wealth fund said they were withdrawing their bid for the drugmaker.

The company in September agreed to an $8 billion takeover by Advent and Aurora, an investment vehicle of Singapore's GIC Pte Ltd, through Agnafit Bidco.

"Since the acceptance level condition has not been fulfilled, Agnafit Bidco hereby withdraws the offer," Agnafit Bidco said in a statement.

Having soared 36% this year through Thursday, Sobi shares were down 23% at 1336 GMT to 174.60 crowns ($19.20).

The 235 crowns per share offer had represented a premium of 34.5% to its Aug. 25 closing price.

Sobi Chairman Hakan Bjorklund said the board, which had supported the bid, was confident the company would deliver on its goals to expand globally, invest in haematology, and expand in immunology and specialty care.

"Subsequent discussions regarding the potential execution of the transaction have been directly dealt with between the bidding consortium and Sobi shareholders," Bjorklund said in a statement.

Sweden's Investor AB, which owns a 35% stake in the rare disease drugmaker, said that its focus would now be to "continue to create long-term value for Sobi's shareholders".

Agnafit said shares corresponding to around 87.3% of outstanding shares in Sobi, which sells drugs within haemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, had been tendered, below its condition of more than 90%.

Anglo-Swedish drugmaker AstraZeneca holds an 8% stake in Sobi, whose best-selling drug, established haemophilia A treatment Elocta with 4.6 billion crowns in 2020 revenue, is facing competition from Roche's Hemlibra.

($1 = 9.1066 Swedish crowns)

(Reporting by Helena Soderpalm, editing by Niklas Pollard and Jason Neely)

By Helena Soderpalm


ę Reuters 2021
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
01/11Avalo Therapeutics Appoints Chief Commercial Officer
MT
2021Swedish Orphan Biovitrum Gets Positive Opinion From European Medicines Agency For COVID..
MT
2021Kineret« (anakinra) receives positive opinion from the CHMP for treatment of patients w..
AQ
2021Kineret« Receives Positive Opinion from the Committee for Medicinal Products for Human ..
CI
2021Swedish Orphan Biovitrum, Apellis Pharmaceuticals Win European Regulatory Nod For Blood..
MT
2021Apellis Pharmaceuticals Receives Approval From European Commission for Aspaveli
MT
2021Aspaveli« (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
AQ
2021Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB Announce EU Approval of A..
CI
2021Swedish Orphan Biovitrum's Rare Blood Disease Therapy Achieves Haemoglobin Normalizatio..
MT
2021Apellis Pharmaceuticals Reports 46% Hemoglobin Normalization in Broad Paroxysmal Noctur..
MT
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Financials
Sales 2021 15 226 M 1 680 M 1 680 M
Net income 2021 2 375 M 262 M 262 M
Net Debt 2021 9 409 M 1 038 M 1 038 M
P/E ratio 2021 22,8x
Yield 2021 -
Capitalization 53 834 M 5 975 M 5 941 M
EV / Sales 2021 4,15x
EV / Sales 2022 3,71x
Nbr of Employees 1 532
Free-Float 59,5%
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 182,40 SEK
Average target price 198,88 SEK
Spread / Average Target 9,03%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Hňkan Bj÷rklund Chairman
Anne Marie de Jonge Schuermans Head-Technical Operations & Senior Vice President
Sven Anders Ullman Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SWEDISH ORPHAN BIOVITRUM AB (PUBL)-2.11%5 975
CSL LIMITED-4.34%96 012
WUXI BIOLOGICS (CAYMAN) INC.-2.54%48 785
SAMSUNG BIOLOGICS CO.,LTD.-8.53%45 861
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-0.26%35 151